Code of Business Conduct
Code of
Business Conduct
At Johnson & Johnson, we believe acting ethically and responsibly is not only the right thing to do, but also the right thing to do for our business. Our Johnson & Johnson Code of Business Conduct ensures that we hold ourselves and how we do business to a high standard, allowing us to fulfill our obligations to the many stakeholders we serve.
Effective March 30, 2020, Johnson & Johnson amended its Code of Business Conduct to provide enhanced guidance on addressing the evolving business environment. Effective January 2, 2023, the title of our Chairman and CEO, Joaquin Duato was updated. No other content changes were made.
Effective March 30, 2020, Johnson & Johnson amended its Code of Business Conduct to provide enhanced guidance on addressing the evolving business environment. Effective January 2, 2023, the title of our Chairman and CEO, Joaquin Duato was updated. No other content changes were made.
Our Credo Integrity Line
Our Credo Integrity Line is an integral component of our strong culture of integrity at Johnson & Johnson. It provides a channel for anyone (including employees, business partners, customers, consumers and others) to report potential violations of the Code of Business Conduct, other company policies or applicable laws and regulations in our countries of operation. Our Credo Integrity Line is available 24 hours a day, 7 days a week and in 24 languages.
Go to the Our Credo Integrity Line website for more information including directions for filing concerns digitally or by phone.
Go to the Our Credo Integrity Line website for more information including directions for filing concerns digitally or by phone.
Additional policies & resources
The values and principles spelled out in Our Credo serve as our compass; the Johnson & Johnson Code of Business Conduct is the road map that helps us stay on course with those values. The Code sets requirements for business conduct and serves as a foundation for our Company policies, procedures and guidelines, all of which provide additional guidance on expected behaviors.
More from Johnson & Johnson
“I couldn’t speak, walk or sit.” Inside a rare autoimmune disease that attacks the muscles
Elisa Glass was diagnosed with dermatomyositis, which causes severe muscle weakness throughout the body. For Myositis Awareness Month, she shares her story.
5 things we now know about bladder cancer
Paradigm-shifting new therapies are helping people with the disease lead longer, more comfortable lives. For Bladder Cancer Awareness Month, learn how Johnson & Johnson is helping to change the treatment landscape.
What is IL-23?
This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.